Sucampo Pharmaceuticals (Nasdaq: SCMP) announced that Swissmedic, the Swiss Agency for Therapeutic Products, has approved AMITIZA (lubiprostone) 24 mcg for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE